BPH, benign prostatic hyperplasia; PCA, prostate cancer; PSA, prostate-specific antigen; MS/MS, tandem mass spectrometry; OCM, Oncomine Concept Map; Benign, benign adjacent prostate; Mets, metastatic prostate tumor; iTRAQ, isobaric tag for relative and absolute quantitation; miRNA, micro ribonucleic acid; Q-PCR, quantitative RT-PCR. we interrogate the proteomic alterations in a cohort of 15 prostate-derived tissues that included five each from adjacent benign prostate (Benign), clinically localized prostate cancer (PCA) and metastatic disease from distant sites (Mets). The experimental strategy couples isobaric tags for relative and absolute quantitation (iTRAQ) with multi-dimensional liquid-phase peptide fractionation followed by tandem mass spectrometry. Over 1000 proteins were quantified across the specimens, and delineated into clinically localized and metastatic prostate cancer-specific signatures. Included in these class-specific profiles were both proteins that were known to be dysregulated during prostate cancer progression and new ones defined by this study. Enrichment analysis of the PCA-specific proteomic signature, to gain insight into the functional consequences of these alterations, revealed involvement of miR-128-a/b regulation during prostate cancer progression. This finding was validated using real time PCR (Q-PCR) analysis for miRNA transcript levels in an independent set of 15 clinical specimens. miR-128 levels were elevated in benign prostate epithelial cell lines compared to invasive prostate cancer cells.
INTRODUCTION
Prostate cancer is the second most common cause of cancer-related death in America and afflicts one of nine men over the age of 65. The American Cancer Society estimates that 186,320
American men will be diagnosed with prostate cancer and 28,660 will die this year [1] . The advent of prostate specific antigen (PSA) screening has led to earlier detection of prostate cancer [2] . Coincident with increased serum PSA testing, there has been a dramatic increase in the number of prostate needle biopsies performed [3] . This has resulted in a surge of equivocal prostate needle biopsies [4] and men with the looming threat of prostate cancer. However, the stage-shift associated with the advent of PSA screening may also be associated with diagnosis of a substantial number of prostate cancer cases that may have non-aggressive clinical natural history, or so-called 'indolent' prostate cancers [5, 6] . Even before the advent of PSA screening, it was noted that up to 70-80% of Gleason score 6 cancers, and as many as 20% of Gleason 7 cancers, may have a non-aggressive course without cancer death if observed without intervention for more than 15 years [7] . With the population of males 65 years and older expected to increase from 14 million in year 2000 to 31 million by 2030 [8] , it will be increasingly important to discern such indolent prostate cancer from aggressive cancers that warrant intervention.
Prostate cancer, like other cancers, develops in the background of diverse genetic and environmental factors [9] . Multiple complex molecular events characterize prostate cancer initiation, unregulated growth, invasion, and metastasis. Distinct sets of genes, proteins and metabolites dictate progression from precursor lesion, to localized disease, and finally to metastatic disease. Clinically localized prostate cancer can be effectively ablated using surgical or radiation treatments. Androgen ablation is the most common therapy for advanced prostate cancer, leading to massive apoptosis of androgen-dependent malignant cells and temporary tumor regression. In most cases, however, the tumor re-emerges, can proliferate independent of androgen or anti-androgen signals, and develops into a metastatic disease which is invariably incurable. With the advent of global profiling strategies, a systematic analysis of molecular alterations involved in prostate cancer is now possible.
Importantly, deciphering the molecular networks that distinguish progressive disease from non-progressive disease will shine light on the biology of aggressive prostate cancer as well 5 as lead to the identification of biomarkers that will aid in the selection of patients who should be treated [10] . To begin to understand prostate cancer progression with a systems perspective, we need to characterize and integrate the molecular components involved [11] [12] [13] [14] . A number of groups have employed gene expression microarrays to profile prostate cancer tissues [15] [16] [17] [18] [19] [20] [21] [22] [23] as well as other tumors [24] [25] [26] [27] at the transcriptome level but much less work has been done at the protein level.
Proteins, as opposed to nucleic acids, represent the functional effectors of cancer progression and thus serve as therapeutic targets as well as markers of disease. Proteomics approaches will facilitate the identification of proteins and biochemical pathways involved in tumor development. Proteomic studies will also facilitate identification of differential posttranslational modifications which play a major role in cellular functions. Nelson et al., carried out protein expression profiles of androgen-stimulated prostate cancer cells using twodimensional electrophoresis [28] . Ahram et al. identified cellular proteomes of matched normal prostate epithelial cells and high-grade prostate cancer cells using a combination of tissue microdissection, two-dimensional electrophoresis, and mass spectrometry [29] . Multiple technologies have been used to identify proteomic alterations in the serum of prostate cancer patients including protein microarray and SELDI [13, 30] . However, studies quantifying proteomic alterations in tumor specimens in an unbiased manner have been limited [31] [32] [33] [34] [35] .
Recently Garbis et al. [32] and Ralhan et al. [35] have used iTRAQ-based quantification to assess global alterations in the proteome using tissues from prostate cancer and head and neck cancer patients, respectively. We have used a similar approach to quantify global changes associated with the prostate cancer proteome in the stages of progression from organ-confined to metastatic disease. Additionally, we extend our analysis beyond delineation of tumor-specific proteomic signatures to nominate and confirm the miR-128 pathway as a critical intermediary in tumor invasion.
EXPERIMENTAL PROCEDURES

Patient Population and Sample Selection
The Institutional Review Board (IRB) of the University of Michigan Medical School approved this study on discovery of proteomic alterations of prostate cancer progression. Tissue 6 samples obtained post-surgery from clinically localized prostate cancer patients (n=5), advanced prostate cancer patients (n=5), and adjacent normal controls (n=5) were procured in a frozen state from the University of Michigan Specialized Research Program in Prostate Cancer (SPORE) tissue bank. Two men provided both tumor and benign tissue samples. All other tissue samples were from unique patients. De-identified numeric specimen codes were used to protect the identity of the men. Detailed clinical and pathology data for this study are available in Supplementary Table 1 . The histological diagnosis of each sample was confirmed by microscopic examination of hematoxylin-and eosin-stained frozen sections by a board certified pathologist.
Chemicals and Reagents
All chemicals were purchased from Sigma (St Louis, MO) unless otherwise mentioned.
Antibodies
Mouse monoclonal antibodies directed to Vimentin, Ezrin, RAN, and FAS and polyclonal antibodies to SLC25A3, TMSB10, and PHB were purchased from BD Biosciences (San Jose, CA) and Novus Biologicals (Littleton, CO), respectively. Goat polyclonal antibodies against ARF1, APRIL and GAPDH were procured from Abcam Inc (Cambridge, MA) while VCP antibodies were purchased from Santa Cruz Biotechnology (Santa Crutz, CA). Antibodies to RAP1B and TROVE 2 were purchased from Cell Signaling Technologies (Danvers, MA) and Genway (San Diego, CA), respectively. Rabbit polyclonal antibodies to GOLM1 were kindly gifted by Dr. Claus J. Fimmel from Edward Hines VA Medical Center, Hines IL.
Protein Extraction
For protein extraction, the tissue samples were re-suspended in lysis buffer consisting of 7M urea, 2 M thiourea, 100mM DTT, 0.5% biolyte 3-10 (Pharmacia, Pitscataway, NJ), 2% octyl glucoside and 1mM PMSF. Samples were lysed at room temperature for 30 minutes, followed by centrifugation at 35,000 rpm at 4 o C for 1 hr. The protein solution was exchanged into 50 mM triethyl ammonium bicarbonate (TEBC), pH=9 using a PD-10 column as per manufacturer's 7 instruction (Pharmacia, Piscataway, NJ). Total protein content was measured using Bradford's assay (BioRad, Hercules, Ca) and the lysates were stored at -80 o C for future use.
Protein Digestion and iTRAQ-labeling
200 µg total protein amount from each tissue sample was used to generate iTRAQlabeled peptides as per the manufacturer's protocol. Specifically, the proteins were first subjected to reduction and alkylation using DTT and IAA provided in the iTRAQ labeling kit (iTRAQ® Reagents Multiplex Kit, Applied Biosystems, Foster City, CA). They were then digested to peptides using Porcine Trypsin (1:50, Promega, Madison, WI) in 50mM triethylammonium bicarbonate (TEBC), pH 9. The digestion was performed for 24h at 37ºC. At the end of 24h, the trypsin activity was stopped using 3% formic acid. The digested peptides were subjected to iTRAQ labeling as per protocol described previously [36] . The iTRAQ experiments were performed in five sets, each containing four samples. Specifically, for labeling, 100 µg protein each from benign, PCA and Met were labeled with isobaric tags 114, 115 and 116, respectively, (Figure 1) . A reference pool containing 67 µg protein from each of the tissue samples (n= 5 each of benign, PCA and Met) used in the study was created (total protein amount in the pool = 1mg) and labeled with isobaric tag 117 (Figure 1 ). 50 µg of peptides labeled with each of the four isobaric labels were combined and subjected to two-dimensional fractionation coupled to tandem mass spectrometry (Figure 1 ).
<< Figure 1 >>
SCX fractionation
200 µg of iTRAQ labeled peptide samples described above were completely dried in a SpeedVac and resuspended in 40 μL of 0.1% formic acid in 5% acetonitrile (mobile phase A)
and directly loaded onto a 1 × 150-mm Poly-SEA strong cation exchange column (Michrom Bioresources, Auburn, CA) using Agilent 1200 auto sampler. Buffer containing 1M ammonium formate, 10% Formic acid in 5% acetonitrile (mobile phase B) was used to create a linear chromatographic gradient at a flow rate of 50µL/min. A total of 10 fractions were collected over a 40 min gradient encompassing a salt concentration of 0-100 mM ammonium formate. An additional 5 fractions were generated over the next 10 minutes at higher salt concentration range 8 of 100-1000 mM. Fractionated peptides were completely dried and reconstituted in 10 µL of 0.1% TFA prior to LC-MS/MS analysis. Offset 2V was used for fragmentation. Reference mass correction was activated using reference mass of 1221.99. Precursors were set in an exclusion list for 0.5 min after two MS/MS spectra.
HPLC-
Mass Spectral Data Analysis
MS/MS spectra generated above were extracted from the raw data in mzXML file format using a converter from the Institute for Systems Biology As the next step, data from the 15 mass spectrometry measurements were merged into a single file. To align proteins with their most likely counterparts across the experiments ( Figure   S1 ) the 15 individual PeptideProphet files were run together through ProteinProphet, and the combined protein file was generated (master protein identification list). In-house written software was then applied to extract, for each protein group in the master list, information from the individual ProteinProphet files (probability, number of spectra, quantitative information). For each protein group in the master file, the IPI accession with the most evidence across the 15 iTRAQ experiments (i.e., reported in the most XML files) was retained. Then, the maximum probability-score (Pw), provided by Protein Prophet, across the 15 iTRAQ experiments was calculated and taken as the primary score for filtering the data. We chose to threshold the data retaining only proteins (i.e. IPI accessions) whose maximum protein probability was at least 0.955. This threshold amounted to an estimated false discovery rate (FDR) of 2% calculated as the number of reverse proteins identified divided by the number of forward proteins identified 
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Given that the same set of proteins was not measured in each ITRAQ experiment and that the quantification is relative we chose to analyze each of the 5 ITRAQ experiments separately.
Specifically, we assume that each experiment is composed of a mixture of three distributions:
10% up-regulated, 10% down-regulated, and 80% unchanged. We assume that on the log 2 scale the unchanged measurements form a symmetric distribution and thus trim the upper 10% and lower 10% of the data points to arrive at a trimmed distribution representing the null or unchanged measurements. We chose the threshold for dysregulation as the mean of the trimmed data plus or minus 1.5 times the standard deviation of the trimmed data. To reduce spurious results, for localized tumor tissue compared to benign adjacent tissue, we required that the protein be detected in at least two samples and that at least two of these samples showed dysregulation in the same direction to be considered further. Proteins with discordant expression patterns within samples of a given diagnostic class were not considered among those dysregulated.
For metastatic tumors versus localized tumors we expected to see more dysregulation so we assumed 20% of the proteins were up-regulated, 20% were down-regulated, and 60% were unchanged. Again, the sample trimmed mean and trimmed standard deviation were used to construct the thresholds. However, as we expect more spurious results due to differences in the site of metastasis, we require the protein to be detected in at least three samples and have concordant results in at least 60% of the samples detected for further consideration.
Heatmap Plots
Heatmaps were drawn using the image function in R [38] . The color coding is derived using the ranking of the log ratio in the distribution of measures for that sample. Shades of green represent down-regulation and shades of red represent up-regulation. The intensity of the color is determined by the distance (in standard deviations) from the mean of the trimmed distribution.
Oncomine Concept Map analyses
Mapping of Proteomics data to a common identifier. Protein identifications (IPI numbers)
belonging to PCA-specific or Met-specific signatures were converted to HUGO gene symbols and batch loaded to Oncomine concept Map (OCM, http://www.oncomine.org.) for analysis as 12 described below. The conversion to gene symbol requires that potential isoforms, i.e. multiple IPI numbers associated with a single gene symbol, contribute only once in the enrichment analysis.
Enrichment of Molecular Concepts. In order to explore the network of inter-relationships among various molecular concepts and our proteomics data, we used the Oncomine Concepts Map (www.oncomine.org) bioinformatics tool developed and widely published by our group, [39] [40] [41] [42] [43] . In addition to being the largest collection of gene sets for association analysis, the Oncomine Concepts Map (OCM) is unique in that computes pair-wise associations among all gene sets in the database, allowing for the identification and visualization of "enrichment networks" of linked concepts. Integration with the OCM allows us to systematically link molecular signatures (i.e., in this case class-specific proteomic profiles) to over 14,000 molecular concepts, confirming previous observations and generating novel hypotheses about the biological progression of prostate cancer. Prior to performing the enrichment analysis for the proteomic data a list of gene IDs was generated from the proteins that were determined to be differential (see Statistical Analysis, above). This signature was used to seed the analysis. Once seeded, each
pair of molecular concepts was tested for association using Fisher's exact test. Each concept was then analyzed independently and the most significant concept reported. Results were stored if a given test had an odds ratio > 1.25 and P-value < 0.01. Adjustment for multiple comparisons was made by computing Q-values for all enrichment analyses [39] . We are confident that the integrative analyses coupled to enrichment using OCM will generate a number of testable hypotheses on molecular events leading to development of cancer and its progression to advanced disease. For the analysis of class-specific proteomic profiles, all concepts that had a Pvalue less than 0.001 were considered significant. A similar enrichment analysis of miR-128a gene expression profiles (see Figure 4e ) was carried out wherein the gene signature was determined by a Q-value threshold of 5% on tests of differential expression. All concepts that had a P-value less than 1X10 -5 were considered significant.
Immunoblot Analysis
Proteins for immunoblotting were resolved by 4-12% NUPAGE gels (Invitrogen) and transferred to PVDF membranes (GE Healthcare Bio-Sciences Corp., Piscataway, NJ). The 13 membranes were blocked with 5% skimmed milk in TBS-T (20mM Tris.Cl, pH 7.4, 150mM
NaCl, 0.1% Tween 20) over-night. Antibodies (indicated in 'Materials') were added in TBS-T containing 2.5% skimmed milk and the blots were washed with TBST. Immunoblot signals were developed using ECL chemiluminescence reagent (GE Healthcare Bio-Sciences Corp.).
RNA interference
PrEC or RWPE cells were treated with non-targeting siRNA (D-001210-01, Dharmacon, Lafayette, CO), siRNA specific to miR-128 (D-003886-01, Dharmacon) as per published protocols [42, 43] .
Quantitative RT-PCR
Q-PCR was performed using Power SYBR Green Mastermix on a 7300 Real Time PCR machine (both Applied Biosystems, Foster City, Ca) as previously described [42] . All primers were designed using Primer 3 and synthesized by Integrated DNA Technologies and are listed in Supplementary Table 8 . All PCR experiments were performed in triplicate.
Micro RNA Q-PCR
For microRNA quantitative PCR, total RNA including small RNA was isolated from prostate tissues, PrEC and DU145 cells that were transfected either with miR-128a (precursor human miRNA-128a), antagomiR-128a [44] used endogenous control (RNU68) to normalize the expression levels of target micro-RNA by correcting differences in the amount of RNA loaded into qPCR reactions.
14 Cell invasion assay.
Cell invasion was carried out using a modified basement membrane chamber assay as previously described [42] . 
RESULTS
Quantitative Assessment of Prostate Cancer Proteome
An overview of the approach we took in quantifying proteomics alterations in prostate cancer is depicted in Figure 1 . In an effort to profile the proteome in the stages of prostate cancer progression, we used a combination of iTRAQ-labeling and two-dimensional liquid chromatography coupled with mass spectrometry to interrogate the relative levels of proteins across 15 prostate-related biospecimens. The two-dimensional fractionation of the labelled peptides involved the use of an offline SCX-based separation in the first dimension followed by an online reverse phase fractionation (Figure 1 ). Each iTRAQ sample set was analyzed in three independent mass spectrometer runs (refer Methods for details). At a protein probability threshold of 0.955 (2% FDR), across the 5 iTRAQ sample sets, a total of 1221 and 1085
proteins were identified by two or more peptides using the two high capacity mass spectrometry runs, respectively, while the low capacity run yielded 967 proteins (Supplementary Table 2 and Figure S3 ). Among these, 777 proteins (56.6%) were shared across the three measurements ( Figure S3 ). There was 72.2% overlap in the proteins identified between the two high capacity runs and 66-69% overlap between any of the high capacity and the low capacity measurements ( Figure S3) . Data from the three independent runs were first combined on a per sample basis using a weighted average and the resulting compendium for each of the 5-iTRAQ sample sets was used for further analysis as described above. Overall To delineate an organ-confined prostate-cancer-specific proteomic signature, the data were first normalized by centering the trimmed mean of proteins in localized prostate cancer samples at 1 (upper and lower 10% of intensity values excluded). Differentials were identified using a threshold set at 1.5-trimmed standard deviations from the trimmed mean. The final list 16 of differentials was restricted to proteins that were concordantly differential in at least two or more samples in a given diagnostic class (See Methods for details). A similar approach was used to define the metastatic prostate cancer specific proteome relative to the localized prostate cancer except that in this case the sample trimmed mean and trimmed standard deviation were calculated by excluding 20% of the outliers in either direction. Further, as we expect more spurious results due to differences in the site of metastasis, we required concordant results in at least 60% of the samples in which the protein was detected, for further consideration. These class specific proteomic alterations are presented in a heat map format as described above (Figure 2 a, b) . [61] , and N-myc downstream regulated gene (NDRG1) [62] , all of which have been earlier reported to be down-regulated in organ-confined disease. Likewise, 141 and 165 proteins were found to be elevated and down-regulated, respectively, in metastatic disease compared to organ-confined cancer (Figure 2b and Supplementary Tables 5 and 6 ). Included in these were proteins that have been previously reported to be perturbed in advanced disease as well those found to be dysregulated by our study (Figure 2b) . Included in the former were enzymes like phosphoglycerate kinase 1 (PGK1) [63] , hydroxysteroid (17-beta) dehydrogenase (HSD17B) [64] , enolase 1 alpha (ENO1/MBP1) [65] , acetyl-Coenzyme A acetyltransferase 1 (ACAT1) [66] and fructose-1,6-bisphosphatase 1 (FBP1) [67] ; oncogenes like stathmin 1/oncoprotein 18 (STMN1) [68] ; and signaling molecules like 14-3-3 protein (YWHAZ) [65] and member of RAS oncogene family (RAN) [69] among others (Figure 2b, left panel) . Additionally, our profiling study for the first time revealed elevated levels of proteins belonging to solute carrier family like SLC25A3 and SLC25A5; splicing factors namely arginine/serine-rich 2 (SFRS2) and splicing factor, arginine/serine-rich 7 (SFRS7) and chaperonins containing TCP1 complex like CCT2, CCT3, CCT5 and CCT8 in metastatic disease compared to organ-confined tumors (Figure 2b, left panel) . Included among the proteins that were down-regulated and reported previously were S100A6 [70] , superoxide dismutase 3 (SOD3) [71] , transforming growth factor, beta 1 (TGFB-1) [72] , destrin (DSTN) [73] , gelsolin (GSN) [74] and lectin, galactoside-binding, soluble, 3 (LGALS3) [75] (Figure 2b , right panel and Supplementary Table 6 ).
We further validated some of these proteomic alterations using immunoblot analysis carried out on independent prostate-related specimens (5 each of benign, PCA and Mets, Figures 18 independent clinical specimens (Figure 2c) . Having validated our mass spectrometry results, we were interested in delineating the biological nuance associated with these proteomic alterations.
Towards this we carried out enrichment analysis of the localized prostate cancer-specific proteomic signature.
<< Figure 3 >>
Analysis of prostate cancer-associated biological processes and pathways by OCM
To determine the ability of our PCA-specific signature to identify pathways that are deregulated during prostate cancer development and progression, we performed an 'Oncomine concept' map analysis (OCM, www.oncomine.org) on the group of proteins that were identified to be upregulated in organ-confined disease compared to benign (see Methods, Supplementary Table 3 for list of proteins used). Our laboratory's recent work in the enrichment analysis of biologically related gene sets allows for the discovery of patterns of shared behavior over a vast database of high-throughput experimental data and biological annotation [40] . Table 7 for list of all concepts within the p-value threshold of 1X10 -3 ). This miR-128 concept was intriguing in the context of a recent study that predicted a decrease in the expression of this micro RNA in breast cancer [76] . However, the functional consequence of this down-regulation has not been described thus far. This motivated us to extend our investigation to understand the consequence of miR-128 deregulation in the context of prostate cancer.
Assessment of miR-128 expression in prostate-derived tissues and cell lines.
miR-128 concepts were enriched in our OCM analysis by eight high confidence proteins (all identified by at least 2 peptides) namely golgi membrane protein 1 (GOLM1), TROVE domain family member 2 (TROVE2), Prohibitin (PHB), solute carrier family 25 (SLC25A3), myristoylated alanine-rich protein kinase C substrate (MARCKS), Heteronuclear ribonucleoprotein (HNRPF), Thymosin Beta 10 (TMSB10), and member of ras oncogene family (RAP1b), all of which were elevated in localized prostate cancer and further were predicted to be targets of the microRNA by picTAR. Towards characterizing the role of miR-128, we first validated the expression of GOLM1, PHB, TROVE2, TMSB10 and SLC25A3 in independent clinical specimens (n=5 each of benign, PCA and Mets) using immunoblot analysis (Figure 3b) .
Next we confirmed deregulation of miR-128 expression in independent clinical specimens using real time PCR analysis (refer Supplementary Table 8 Specifically, transcript levels for miR-128 were significantly decreased in PCA compared to BPH samples (t-test with Satterthwaite correction for unequal variances, p=0.016).
Additionally, miR-128 transcript levels displayed an even greater down-regulation in the metastatic samples compared to organ-confined disease ( Figure. 3c, p=0 .0017).
To determine whether miR-128 down-regulation in prostate cancer has biological relevance, we employed prostate cancer cell line DU145 and its benign epithelial counterpart, primary benign prostate epithelial cells (PrEC). Using these cell lines, we assessed their transcript levels for miR-128 using Q-PCR. As shown in Figure. 4a, the prostate cancer cell line DU145 displayed lower levels of miR-128 (one-sample t-test, p=0.0002, n=3) compared to their benign epithelial counterparts. This was in line with our earlier observation with prostate tissues wherein a decrease in expression of the micro-RNA correlated with aggressivity of the disease. Figure 6 ). Similar induction of invasive phenotype accompanying an attenuation of miR-128 levels was also observed using an independent benign transformed epithelial cell line (RWPE, data not shown).
These validated a role for miR-128 in regulating tumor invasion.
To get additional insights, we carried out gene expression analysis of benign prostate epithelial cells (PrEC) upon over expression of miR-128a. Genes that were down-regulated upon the over expression of the micro-RNA were used for enrichment analysis using Oncomine Concepts Map (www.oncomine.org) [39, 40] , (refer Figure 4e and Supplementary Table 9 for list of all concepts within the p-value threshold of 1X10 -5 ). Included in the list of concepts enriched by the "miR-128a targets" (Figure 4e , miR-128a_KD) were those that described regulation of cell cycle (Figure 4e, green bridges) . Notably, this served as a reference for our analysis as earlier reports have confirmed a role for miR-128 in cell cycle regulation through its 21 control of E2F3 expression [78] . Of more interest to us, however, was the enrichment of multiple concepts, all of which described invasive tumors or those with poor outcome (Figure 4e , red bridges). These included gene expression-derived concepts for aggressive tumors of breast, lung, liver and ovary (Figure 4e, red bridges) . This observation further strengthened our in vitro findings implicating miR-128 in cancer aggressivity especially the process of tumor invasion.
DISCUSSION
By coupling multidimensional protein fractionation and quantitative mass spectrometry with bioinformatics-based enrichment analysis we demonstrate the involvement of miR-128 in the stages of prostate cancer progression. The proteomic signatures quantified in both organconfined and metastatic samples contained proteins that have been previously implicated in this disease. Significant among these were multiple proteins belonging to the secretory or endocytic pathways. This included the golgi-associated antigen, GOLM1, that has been recently reported from our laboratory to be elevated both at the transcript and protein level in localized tumors [45] . Similarly STEAP4, known to be androgen regulated and involved in endocytic trafficking [52] was elevated in localized tumors. An important finding from our profiling data was the elevation in levels of multiple proteins that contain leucine-rich protein interacting motifs.
Included in this was the phospho-protein pp32r1 that belongs to the ANP32 family. This protein has been shown to be oncogenic with very high levels of expression in prostate adenocarcinoma cell lines [79] . Additional findings from our data included elevated levels of DNA binding and GTP binding proteins, respectively, confirming increase transcriptional activity and signaling during early cancer development. The metastatic signature on the other hand showed elevated levels of multiple arginine-serine rich pre-mRNA splicing factors. This is relevant in the context of existing knowledge that implicate these in cancer development [80] . Also our "Up in Metastatic" signature revealed elevated levels of solute carrier proteins namely SLC25A5 and SLC25A3. The former has been implicated earlier to be elevated in lymph node metastasis associated with hepatocellular carcinoma [81] , whereas SLC25A3 serves as the mitochondrial transporter for phosphate [82] . Interestingly, independent metabolomic data for prostate cancer progression generated by our laboratory revealed significantly elevated levels of inorganic phosphate in tumors corroborating with the finding of elevated levels of phosphate carrier in metastatic prostate cancer [83] .
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Importantly, extending beyond revealing single molecule alterations, we interrogated biological significance of these alterations in the context of prostate cancer development/progression using OCM. An enrichment of miR-128 concepts by the tumor-specific signature was revealed. This was exciting since studies from our laboratory and others have implicated microRNAs in regulating tumor progression [84] and invasiveness [85] . Remarkably, to our knowledge this is one of the first studies wherein mass spectrometry-based protein profiling has been combined with bioinformatics-driven enrichment to nominate a microRNA in and 116, respectively, while a pool containing equal amounts of tissue from all the 15 prostatederived samples used in the study was labeled using isobaric tag 117. The 4-plex mixture of peptides were separated using strong cation exchange chromatography and the fractions were analyzed using MS/MS on a 6520 Agilent Q-TOF after online reverse phase pre-fractionation on an HPLC Chip. The spectral data were searched by X-tandem using the human IPI database appended with reverse sequences. Statistical assessment of the search results used 
